Influenza vaccine - Gritstone bio
Latest Information Update: 26 Apr 2023
At a glance
- Originator Gritstone bio
- Class Influenza virus vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 11 Apr 2023 Preclinical trials in Influenza virus infections prevention (Prevention) in USA (unspecified route) (Gritstone bio pipeline, April 2023)
- 19 Dec 2022 Gritstone bio has patent protection for antigen-encoding samRNA vectors and its applicability across candidates in oncology and infectious disease in USA
- 07 May 2018 Gritstone Oncology receives patent allowance for its EDGE™ technology in USA